Public Profile

VYNE Therapeutics Inc.

VYNE Therapeutics Inc., a biopharmaceutical company headquartered in the United States, is dedicated to developing innovative therapies for patients with unmet medical needs. Founded in 2017, VYNE focuses on dermatology and immunology, leveraging its proprietary drug delivery technologies to create unique formulations that enhance treatment efficacy. The company’s flagship product, Amzeeq, is a topical minocycline formulation that addresses acne vulgaris, showcasing VYNE's commitment to advancing patient care through novel solutions. With a strong market position, VYNE Therapeutics has achieved significant milestones, including successful product launches and strategic partnerships, solidifying its reputation as a leader in the biopharmaceutical industry.

DitchCarbon Score

How does VYNE Therapeutics Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

13

Industry Average

Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

14

Industry Benchmark

VYNE Therapeutics Inc.'s score of 13 is lower than 65% of the industry. This can give you a sense of how well the company is doing compared to its peers.

35%

VYNE Therapeutics Inc.'s reported carbon emissions

VYNE Therapeutics Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. As a result, there are no reported figures for their Scope 1, 2, or 3 emissions. The absence of emissions data suggests that VYNE may still be in the early stages of developing a comprehensive climate strategy or reporting framework. In the context of the pharmaceutical industry, companies are increasingly recognising the importance of sustainability and climate commitments. While VYNE has not disclosed specific initiatives or targets, the industry trend indicates a growing emphasis on reducing carbon footprints and enhancing environmental responsibility. As VYNE Therapeutics progresses, it may establish clearer climate commitments and reduction strategies in alignment with industry standards.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. VYNE Therapeutics Inc.'s primary industry is Chemicals nec, which is medium in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. VYNE Therapeutics Inc. is headquartered in US, which has a rank of low, indicating low grid carbon intensity.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

VYNE Therapeutics Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero

Similar Organizations

Verrica Pharmaceuticals Inc.

US
Chemicals nec
Updated 16 days ago

Weave Communications, Inc.

US
Computer and related services (72)
Updated 13 days ago

Henry Schein

US
Medical, precision and optical instruments, watches and clocks (33)
Updated 9 days ago

Arcutis Biotherapeutics, Inc.

US
Chemicals nec
Updated 16 days ago

Solutionreach, Inc.

US
Computer and related services (72)
Updated 15 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers